Literature DB >> 7694530

Overdose of risperidone.

K Brown1, H Levy, C Brenner, S Leffler, E L Hamburg.   

Abstract

Risperidone is an investigational antipsychotic agent currently being tested in an international multicenter drug trial. We report the first case of a risperidone overdose in an apparent suicide attempt. This was without serious clinical side effects and manifested mainly as ECG abnormalities.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7694530     DOI： 10.1016/s0196-0644(05)80421-4

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN： 0196-0644            Impact factor:   5.721


  10 in total

Review 1.  Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death.

Authors:  Karine Titier; Pierre-Olivier Girodet; Hélène Verdoux; Mathieu Molimard; Bernard Bégaud; Wilhelm Haverkamp; Malcolm Lader; Nicholas Moore
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  Inhibition of cloned hERG potassium channels by risperidone and paliperidone.

Authors:  Hong Joon Lee; Jin-Sung Choi; Bok Hee Choi; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-03-06       Impact factor: 3.000

Review 3.  A risk-benefit assessment of risperidone in schizophrenia.

Authors:  V A Curtis; R W Kerwin
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

4.  Risperidone-induced action potential prolongation is attenuated by increased repolarization reserve due to concomitant block of I(Ca,L).

Authors:  Torsten Christ; Erich Wettwer; Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-06-16       Impact factor: 3.000

Review 5.  Antipsychotic-induced hyponatraemia: a systematic review of the published evidence.

Authors:  Didier Meulendijks; Cyndie K Mannesse; Paul A F Jansen; Rob J van Marum; Toine C G Egberts
Journal:  Drug Saf       Date:  2010-02-01       Impact factor: 5.606

Review 6.  A systematic review of cardiovascular effects after atypical antipsychotic medication overdose.

Authors:  Hock Heng Tan; Jason Hoppe; Kennon Heard
Journal:  Am J Emerg Med       Date:  2009-06       Impact factor: 2.469

Review 7.  Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports.

Authors:  W Victor R Vieweg; Mehrul Hasnain; Jules C Hancox; Adrian Baranchuk; Geneviève C Digby; Christopher Kogut; Ericka L Breden Crouse; Jayanthi N Koneru; Anand Deshmukh; Ananda K Pandurangi
Journal:  Psychopharmacology (Berl)       Date:  2013-06-30       Impact factor: 4.530

Review 8.  QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.

Authors:  Mehrul Hasnain; W Victor R Vieweg
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

9.  New Generation Antipsychotic Drugs and QTc Interval Prolongation.

Authors:  W VictorR Vieweg
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-10

Review 10.  Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia.

Authors:  S Grant; A Fitton
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.